BiotechTube

C.difficile vaccine

Phase 3Recruiting
0 views this week 0 watching⚡ Active
Interest: 47/100
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Clostridioides Difficile Associated Disease

Conditions

Clostridioides Difficile Associated Disease

Trial Timeline

Dec 10, 2025 → Jun 7, 2029

NCT ID
NCT07282665

About C.difficile vaccine

C.difficile vaccine is a phase 3 stage product being developed by Pfizer for Clostridioides Difficile Associated Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07282665. Target conditions include Clostridioides Difficile Associated Disease.

What happened to similar drugs?

0 of 3 similar drugs in Clostridioides Difficile Associated Disease were approved

Approved (0) Terminated (1) Active (2)
❌Ridinilazole + VancomycinSummit TherapeuticsPhase 3
🔄Ridinilazole + VancomycinSummit TherapeuticsPhase 3
🔄SER-109Seres TherapeuticsPhase 3

Hype Score Breakdown

Clinical
17
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT07282665Phase 3Recruiting

Competing Products

7 competing products in Clostridioides Difficile Associated Disease

See all competitors
ProductCompanyStageHype Score
AZD5148AstraZenecaPhase 2
42
AZD5148 + PlaceboAstraZenecaPhase 1
29
Ridinilazole + VancomycinSummit TherapeuticsPhase 3
29
Ridinilazole + VancomycinSummit TherapeuticsPhase 3
37
REC-3964Recursion PharmaceuticalsPhase 2
21
SER-109Seres TherapeuticsPre-clinical
16
SER-109Seres TherapeuticsPhase 3
30